RIDDLE&CODE
5.4.2022 10:17:07 CEST | Business Wire | Press release
RIDDLE&CODE Energy Solutions, a 50:50 joint venture between Wien Energie and RIDDLE&CODE, has joined the 2Tokens consortium as a founding member for the Energy Token working group. After having been an associated partner since 2020, the company’s decision to become an active contributor is a consequent step on its path to developing an international service portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005131/en/
The main goal of the collaboration is to turn 2Tokens into the leading European consortium in the industrial blockchain and finance space, representing and supporting the most relevant projects. "We have proven the technical and economic viability of tokenizing energy assets in several individual projects at the regional level. Now it is time to think on a larger scale. The token standards being developed at 2Tokens will most likely have a decisive impact on the future standards of the European energy market,” says Kai Siefert, the newly appointed managing director of RIDDLE&CODE Energy Solutions.
“The joining of a true pioneer such as RIDDLE&CODE Energy Solutions will significantly strengthen European collaboration in the tokenization sector,” underlines Alex Bausch, Executive Chairman of 2Tokens. “RIDDLE&CODE Energy Solutions plays an important role in the adoption of tokenization technology in commercial projects with interoperable banking grade solutions. Our working groups on the EURO stable coin and Energy Tokens are paramount to the joint mission for mass adoption of token technology in the energy industry. “
Next steps: Apart from driving things forward in the 2Tokens working groups, leading 2Tokens members, as well as the RIDDLE&CODE group companies, will discuss commercial partnerships in the areas of Custody of Digital Assets, Tokenization platforms and blockchain hardware research. "For critical infrastructures and in order to turn our European values of democratic governance and the Rule of Law into efficient backend solutions, we need infrastructure that is secure from end-to-end. Crypto hardware anchors will play a key role in this, and that's why 2Tokens is excited to have RIDDLE&CODE joining as the leading European blockchain interface company,” says Jos Röling, Captain of the Energy working group.
About RIDDLE&CODE Energy Solutions
RIDDLE&CODE Energy Solutions provides the blockchain-powered infrastructure that enables resilient, decentralized and fully decarbonized energy markets. With the development of the MyPower platform, the company has shown an effective way for energy players to move into the machine economy. By tokenizing energy, machines, and data, RIDDLE&CODE Energy Solutions significantly increases the liquidity of distributed assets, making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.
More information about MyPower: www.riddleandcode.com/energy
About 2Tokens
2Tokens has the ambition to raise awareness, stimulate relevant discussions, and bring together knowledge/expertise to reduce the barriers to the adoption of tokenization and help realise wider social benefits. The mission of 2Tokens is to formulate a guide, as part of a larger vision, for any type of organisation that wants to leverage token technology. It aims to come to a shared understanding of token finance and, as such, is a public-interest initiative supported by a diverse community of technology companies, policymakers, financial advisors, banks, and legal & regulatory experts and academia. 2Tokens is a non-profit organisation funded in part by the European Union and Industry partners with the endorsement of the Erasmus University Rotterdam, government and several industry players.
More information: www.2tokens.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom